Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HHAT | Q5VTY9 | 2/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24490312 | 0.86 | DRD1 (0.44) | DRD1MTNR1BACEMEN1MAPT | |
| SCHEMBL24490306 | 0.86 | DRD1 (0.44) | DRD1MTNR1BACEMEN1MAPT | |
| SCHEMBL22461287 | 0.82 | MTNR1B (0.50) | DRD1KRASMTNR1BACEHHAT | |
| SCHEMBL18711615 | 0.81 | DRD1 (0.60) | DRD1MTNR1BRIPK1AKR1C3LIPE | |
| SCHEMBL21465733 | 0.81 | DRD1 (0.60) | DRD1MTNR1BRIPK1AKR1C3LIPE | |
| SCHEMBL30878500 | 0.81 | DRD1 (0.60) | DRD1MTNR1BRIPK1AKR1C3LIPE | |
| SCHEMBL10312392 | 0.81 | DRD1 (0.60) | DRD1MTNR1BRIPK1AKR1C3LIPE | |
| SCHEMBL22461413 | 0.81 | HHAT (0.45) | DRD1MTNR1BRIPK1ACEHHAT | |
| SCHEMBL22461414 | 0.81 | HHAT (0.45) | DRD1MTNR1BRIPK1ACEHHAT | |
| SCHEMBL22461135 | 0.81 | HHAT (0.45) | DRD1MTNR1BRIPK1ACEHHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | DRD1 4133/4885KRAS 536/4885MTNR1B 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.